8-K: Kalaris TH103 Phase 1a nAMD Data Shows Strong Efficacy

Kalaris Therapeutics announced positive initial Phase 1a data for its TH103 treatment for neovascular age-related macular degeneration, demonstrating significant visual and anatomic improvements and potential for extended durability.

Summary

• Initial data from the Phase 1a single ascending dose (SAD) clinical trial of TH103 in treatment-naive neovascular age-related macular degeneration (nAMD) patients (N=13) who completed 6 months of follow-up demonstrated clinically meaningful improvements in vision and retinal anatomy.
• Rapid and robust response was observed at 1 month, including a mean 10-letter improvement in Best Corrected Visual Acuity (BCVA), a mean 129 µm improvement in mean central subfield thickness (CST), and a mean approximately 95% reduction in central subfield intraretinal fluid (IRF).
• TH103 was generally well tolerated across all dose levels (0.5 mg, 1.5 mg, 2.5 mg), with no dose-limiting toxicities (DLTs) or TH103-related serious adverse events (SAEs) observed.
• Two cases of transient, mild-moderate intraocular inflammation (IOI) were observed at Day 4 in two subjects dosed at 2.5 mg, attributed to host cell protein levels; additional processing steps were implemented, resulting in zero new IOI instances in six additional subjects treated with purified material.
• Pharmacokinetic (PK) analysis showed plasma levels of TH103 dose adjusted mean Cmax were 27 to 51-fold lower compared to current leading anti-VEGF agents, consistent with enhanced intraocular retention and reduced systemic exposure.
• Following a single TH103 injection, 31% of patients received no additional anti-VEGF treatment during the entire six-month follow-up period, suggesting the potential for extended treatment durability.
• The company is accelerating its clinical development program and continues to enroll patients in an ongoing Phase 1b/2 multi-ascending dose, dose-finding study, with preliminary data expected in the second half of 2026.

Sentiment

Score: 8

Explanation: The initial Phase 1a data for TH103 are highly positive, demonstrating strong efficacy, a favorable safety profile (with a manufacturing issue successfully addressed), and promising signals for extended durability and reduced systemic exposure compared to existing treatments. This accelerates the development program and positions TH103 as a potentially differentiated therapy for nAMD, though it is still in early clinical stages.

Positives

• Mean 10-letter Best Corrected Visual Acuity (BCVA) improvement at Month 1 across all dose levels.
• Mean 129 µm improvement in mean central subfield thickness (CST) at Month 1.
• Mean approximately 95% reduction in central subfield intraretinal fluid (IRF) at Month 1.
• TH103 was generally well tolerated, with no dose-limiting toxicities (DLTs) or TH103-related serious adverse events (SAEs) observed.
• No instances of TH103-related retinal vascular occlusive disease, retinal vasculitis, cataracts, or elevated intraocular pressure were observed.
• An updated manufacturing process successfully eliminated intraocular inflammation (IOI) in subsequent patients treated with purified material at the 2.5 mg dose level.
• Pharmacokinetic profile showed dose-adjusted mean Cmax plasma levels 27 to 51-fold lower compared to current leading anti-VEGF agents, indicating enhanced intraocular retention and reduced systemic exposure.
• 31% of patients required no additional anti-VEGF treatment for six months after a single TH103 injection, suggesting potential for extended durability.
• The company is accelerating its clinical development program based on these positive initial Phase 1a data.

Negatives

• Two cases of transient, mild-moderate intraocular inflammation (IOI) were observed at Day 4 in two subjects dosed at 2.5 mg, which were attributed to levels of host cell protein in the original drug product.

Risks

• Risks associated with the clinical development and regulatory approval of TH103, including potential delays in the completion of clinical trials.
• Uncertainties regarding whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials.
• Risks related to the inability to obtain sufficient additional capital to continue to advance the product candidate.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Risks related to the failure to realize any value from any product candidates being developed due to inherent risks and difficulties involved in successfully bringing product candidates to market.
• The ability to obtain, maintain, and protect intellectual property rights related to product candidates.
• Changes in regulatory requirements and government incentives.
• The company's competitive position and expectations regarding developments and projections relating to its competitors and any competing therapies that are or become available.
• The risk of involvement in current and future litigation.

Future Outlook

The company is accelerating its clinical development program for TH103 based on positive Phase 1a data. It continues to enroll patients in an ongoing Phase 1b/2 multi-ascending dose, dose-finding study, with preliminary data expected in the second half of 2026. Plans include advancing TH103 into Phase 3 clinical trials and developing it for additional indications such as Diabetic Macular Edema / Diabetic Retinopathy and Retinal Vein Occlusion.

Management Comments

• Dr. Napoleone Ferrara, Kalaris scientific co-founder and board member, stated: "These initial Phase 1a data are highly encouraging and validate the molecular engineering approach we pursued in developing TH103. We believe the rapid visual and anatomic improvements we observed are consistent with potent VEGF inhibition."
• Andrew Oxtoby, Chief Executive Officer of Kalaris, added: "These data are consistent with what was observed in preclinical studies and reinforce what we would expect based on TH103s molecular design. The pharmacokinetic profile and retreatment data provide early signals that the enhanced intraocular retention designed into the molecule may translate to extended clinical durability and reduce the treatment burden for patients."

Industry Context

Neovascular Age-Related Macular Degeneration (nAMD) is a leading cause of vision loss, affecting millions globally. While existing anti-VEGF therapies have significantly improved outcomes, many patients require frequent injections, leading to suboptimal adherence and compromised results. TH103 is engineered to address this unmet need by achieving extended intraocular retention and enhanced VEGF inhibition, potentially offering a more durable treatment option and reducing the burden of frequent injections.

Comparison to Industry Standards

• TH103 demonstrated a mean 10-letter BCVA improvement at Month 1, which is comparable to or slightly better than current market-leading agents like Eylea (VIEW 1&2: ~9.3 letters, PULSAR: ~8.8 letters, T&L: ~8.4 letters), Eylea HD (~10.8 letters), and Vabysmo (~10.8 letters) in treatment-naive nAMD patients.
• TH103 showed a mean 129 µm improvement in mean CST at Month 1, which is comparable to or better than Eylea (VIEW 1&2: ~105 µm, PULSAR: ~115 µm, T&L: ~110 µm), Eylea HD (~125 µm), and Vabysmo (~120 µm).
• The pharmacokinetic profile of TH103 showed dose-adjusted mean Cmax plasma levels 27 to 51-fold lower than Eylea (2mg), Eylea HD (8mg), and Vabysmo (6mg), suggesting superior intraocular retention and reduced systemic exposure compared to these leading anti-VEGF agents.
• The single-dose durability signal, with 31% of patients requiring no retreatment for six months, suggests potential for extended durability beyond current standard regimens, which typically involve frequent injections.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for future value creation, and accelerated development of a key product candidate.
• Patients with nAMD: Potential for a new, more effective, and less burdensome treatment option with extended durability, potentially improving quality of life and treatment adherence.
• Healthcare Providers: Potential for a new therapeutic option that could improve patient outcomes and reduce the frequency of injections.
• Competitors: Increased competitive pressure in the anti-VEGF market for nAMD, potentially driving further innovation.

Next Steps

• Continue enrolling patients in an ongoing Phase 1b/2, multi-ascending dose, dose-finding study evaluating four monthly loading injections of TH103.
• Identify the optimal dose and regimen for potential Phase 3 development.
• Share preliminary data from the ongoing Phase 1b/2 study in the second half of 2026.
• Planned expansions beyond nAMD into other prevalent VEGF-mediated diseases such as Diabetic Macular Edema / Diabetic Retinopathy, and Retinal Vein Occlusion.

Key Dates

Recommendation

The initial Phase 1a data for TH103 are exceptionally strong, demonstrating rapid and robust improvements in visual acuity and retinal anatomy that are competitive with or superior to current market leaders. The significantly lower systemic exposure and strong signals for extended durability after a single injection suggest a potentially best-in-class profile that could substantially reduce treatment burden for nAMD patients. The successful resolution of the initial manufacturing-related inflammation issue further de-risks the program. While early-stage, these results provide a compelling basis for a 'strong buy' recommendation, anticipating significant future value as the drug progresses through accelerated clinical development and potentially into broader indications.

Keywords

Kalaris Therapeutics, KLRS, TH103, neovascular age-related macular degeneration, nAMD, Phase 1a clinical trial, anti-VEGF, retinal diseases, ophthalmology, biopharmaceutical, clinical data, visual acuity, intraocular retention, drug durability